Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01916447 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT01916447 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 65 participants.
The verdict
NCT01916447, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors.
Interventions
- DRUG Bevacizumab
- DRUG TAS-102
- DRUG CPT-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01916447
The ClinicalTrials.gov registry entry for NCT01916447 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01916447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01916447 about?
NCT01916447 is a clinical study titled "A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.". The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors.
What is the current status of trial NCT01916447?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2013-09. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01916447?
The interventions under investigation include: Bevacizumab (DRUG), TAS-102 (DRUG), CPT-11 (DRUG).
Who is sponsoring clinical trial NCT01916447?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.